112 related articles for article (PubMed ID: 35925070)
21. Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancer.
Tsang ES; Walker EJ; Carnevale J; Fisher GA; Ko AH
Immunotherapy; 2021 Oct; 13(15):1249-1254. PubMed ID: 34338034
[TBL] [Abstract][Full Text] [Related]
22. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Moffat GT; O'Reilly EM
Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
[TBL] [Abstract][Full Text] [Related]
23. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
[TBL] [Abstract][Full Text] [Related]
24. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz HJ; Atasoy A; Shangguan T; Zhao H; El-Rayes B
Oncologist; 2019 Nov; 24(11):1453-1461. PubMed ID: 31147488
[TBL] [Abstract][Full Text] [Related]
25. An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer.
Prete AA; Procaccio L; Bergamo F; Rasola C; Nappo F; Zagonel V; Lonardi S
Curr Oncol; 2022 Jan; 29(2):544-550. PubMed ID: 35200549
[TBL] [Abstract][Full Text] [Related]
26. Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities.
Lee MS; Pant S
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-13. PubMed ID: 33929876
[TBL] [Abstract][Full Text] [Related]
27. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.
Lee V; Murphy A; Le DT; Diaz LA
Oncologist; 2016 Oct; 21(10):1200-1211. PubMed ID: 27412392
[TBL] [Abstract][Full Text] [Related]
28. An evaluation of olaparib for the treatment of pancreatic cancer.
Vaishampayan UN
Expert Opin Pharmacother; 2021 Mar; 22(4):521-526. PubMed ID: 33094666
[TBL] [Abstract][Full Text] [Related]
29. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
[TBL] [Abstract][Full Text] [Related]
30. Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Biliary Tract Cancers Associated with Lynch Syndrome.
Cloyd JM; Chun YS; Ikoma N; Vauthey JN; Aloia TA; Cuddy A; Rodriguez-Bigas MA; Nancy You Y
J Gastrointest Cancer; 2018 Mar; 49(1):93-96. PubMed ID: 29238914
[TBL] [Abstract][Full Text] [Related]
31. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Steiner M; Loman N; Bowen K; Fielding A; Domchek SM
J Clin Oncol; 2015 Jan; 33(3):244-50. PubMed ID: 25366685
[TBL] [Abstract][Full Text] [Related]
32. Microsatellite instability in saliva from patients with hereditary non-polyposis colon cancer and siblings carrying germline mismatch repair gene mutations.
Hu P; Lee CW; Xu JP; Simien C; Fan CL; Tam M; Ramagli L; Brown BW; Lynch P; Frazier ML; Siciliano MJ; Coolbaugh-Murphy M
Ann Clin Lab Sci; 2011; 41(4):321-30. PubMed ID: 22166501
[TBL] [Abstract][Full Text] [Related]
33. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
34. Is the controversy on breast cancer as part of the Lynch-related tumor spectrum still open?
Grandval P; Barouk-Simonet E; Bronner M; Buisine MP; Moretta J; Tinat J; Olschwang S
Fam Cancer; 2012 Dec; 11(4):681-3. PubMed ID: 22890886
[TBL] [Abstract][Full Text] [Related]
35. Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system.
Hirsch D; Gaiser T; Merx K; Weingaertner S; Forster M; Hendricks A; Woenckhaus M; Schubert T; Hofheinz RD; Gencer D
J Cancer Res Clin Oncol; 2021 Jan; 147(1):263-273. PubMed ID: 32776177
[TBL] [Abstract][Full Text] [Related]
36. Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency.
Pang X; Qian J; Jin H; Zhang L; Lin L; Wang Y; Lei Y; Zhou Z; Li M; Zhang H
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636238
[TBL] [Abstract][Full Text] [Related]
37. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
Javle M; Shacham-Shmueli E; Xiao L; Varadhachary G; Halpern N; Fogelman D; Boursi B; Uruba S; Margalit O; Wolff RA; Golan T
JAMA Oncol; 2021 May; 7(5):693-699. PubMed ID: 33662100
[TBL] [Abstract][Full Text] [Related]
38. Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale.
Wang Y; Cuggia A; Pacis A; Boileau JC; Marcus VA; Gao ZH; Chong G; Foulkes WD; Zogopoulos G
J Natl Compr Canc Netw; 2021 Aug; 19(8):883-887. PubMed ID: 34416708
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of metastatic colorectal cancer with synchronous
Cheng Y; Fang XF; Hu HG; Wang J; Sun LF; Yuan Y
Immunotherapy; 2020 Mar; 12(4):229-234. PubMed ID: 32172642
[TBL] [Abstract][Full Text] [Related]
40. The Clinical Significance of Microsatellite Instability in Precision Treatment.
Huang Z; Chen X; Liu C; Cui L
Methods Mol Biol; 2020; 2204():33-38. PubMed ID: 32710312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
